aim
compar
therapeut
efficaci
prolong
macrolid
pmc
corticosteroid
cst
doxycyclin
dxc
levofloxacin
lfx
macrolideunrespons
mycoplasma
pneumonia
mp
pneumonia
children
evalu
safeti
secondari
treatment
agent
method
retrospect
analyz
data
patient
mp
pneumonia
hospit
januari
april
macrolideunrespons
clinic
defin
persist
fever
hour
macrolid
treatment
case
divid
four
group
pmc
cst
dxc
lfx
compar
time
defervesc
ttd
secondari
treatment
ttd
initi
macrolid
treatment
group
adjust
use
propens
scorematch
analysi
result
among
case
mp
pneumonia
unrespons
macrolid
proport
patient
achiev
defervesc
within
hour
cst
dxc
lfx
group
respect
ttd
initi
macrolid
treatment
differ
pmc
cst
group
vs
day
p
pmc
dxc
group
vs
day
p
pmc
lfx
group
vs
day
p
side
effect
observ
cst
dxc
lfx
group
conclus
chang
secondari
treatment
show
better
efficaci
compar
pmc
children
macrolideunrespons
mp
pneumonia
studi
need
guid
appropri
treatment
children
mp
pneumonia
mycoplasma
pneumonia
mp
one
common
pathogen
communityacquir
pneumonia
children
adolesc
caus
varieti
clinic
manifest
mild
respiratori
symptom
sever
fatal
pneumonia
extrapulmonari
given
increas
mrmp
secondari
treatment
agent
corticosteroid
tetracyclin
fluoroquinolon
consid
treatment
mrmp
pneumonia
although
sever
studi
suggest
macrolid
clinic
efficaci
treatment
mrmp
tetracyclin
includ
minocyclin
doxycyclin
report
altern
agent
children
mrmp
howev
recommend
use
patient
younger
year
age
tetracyclin
caus
tooth
discolor
children
period
osteogenesi
odontogenesi
addit
fluoroquinolon
associ
risk
musculoskelet
toxic
includ
tendin
arthriti
growth
impair
children
although
still
lack
inform
safeti
children
report
clinic
detect
advers
event
year
treatment
levofloxacin
lfx
studi
report
clinic
effect
system
corticosteroid
cst
treatment
refractori
mp
pneumonia
hyperreact
host
immun
system
may
contribut
pathogenesi
howev
cst
also
caus
sever
side
effect
growth
disord
glucos
intoler
suppress
immun
system
aim
compar
therapeut
efficaci
prolong
macrolid
pmc
cst
doxycyclin
dxc
lfx
macrolideunrespons
mp
pneumonia
children
evalu
safeti
cst
dxc
lfx
retrospect
analyz
medic
record
patient
mp
pneumonia
age
year
old
hospit
gil
medic
center
januari
april
diagnosi
mp
pneumonia
confirm
follow
condit
satisfi
sign
symptom
fever
cough
dyspnea
product
sputum
chest
pain
abnorm
breath
sound
pneumonia
abnorm
chest
xray
find
compat
pneumonia
identif
mp
igm
antibodi
perform
ill
via
enzymelink
immunosorb
assay
among
patient
macrolideunrespons
mp
pneumonia
case
clinic
defin
persist
fever
hour
macrolid
treatment
studi
macrolideunrespons
mp
pneumonia
case
divid
four
group
pmc
cst
dxc
lfx
pmc
group
defin
case
treat
pmc
without
chang
antibiot
cst
dxc
lfx
group
defin
case
treatment
ad
cst
chang
secondari
treatment
dxc
lfx
persist
symptom
despit
macrolid
treatment
patient
follow
exclud
patient
clinic
symptom
radiolog
find
compat
pneumonia
despit
posit
mp
igm
patient
histori
mp
infect
within
past
year
patient
whose
fever
subsid
within
hour
macrolid
treatment
patient
prescrib
oseltamivir
proven
influenza
hospit
period
patient
secondari
treatment
start
hour
last
time
fever
mean
durat
administr
cst
dxc
lfx
group
day
oral
prednisolon
dosag
mgkgday
intraven
methylprednisolon
dosag
mgkgday
day
dosag
mgkgday
day
dosag
mgkgday
collect
data
includ
age
sex
hospit
period
durat
fever
febril
day
macrolid
treatment
febril
day
macrolid
singl
treatment
time
defervesc
ttd
initi
macrolid
treatment
ttd
secondari
treatment
chest
xray
find
prescrib
antibiot
extrapulmonari
symptom
hepat
skin
rash
arthriti
hematolog
neurolog
symptom
oxygen
use
intens
care
unit
icu
hospit
percutan
cathet
drainag
pcd
insert
rehospit
side
effect
associ
secondari
treatment
cst
dxc
lfx
chest
xray
find
record
read
two
radiologist
classifi
accord
presenc
consolid
lobar
patchi
reticular
opac
pneumon
infiltr
parapneumon
effus
addit
inform
mix
infect
respiratori
pathogen
identifi
multiplex
revers
transcriptionpolymeras
chain
reaction
rtpcr
respiratori
virus
nasopharyng
swab
includ
compar
ttd
secondari
treatment
use
combin
antibiot
requir
treatment
outcom
among
cst
dxc
lfx
group
addit
compar
ttd
initi
macrolid
treatment
length
hospit
stay
pmc
group
vs
cst
dxc
lfx
group
adjust
variabl
could
affect
fever
durat
perform
propens
score
ps
match
analysi
side
effect
cush
appear
peptic
ulcer
cst
tooth
discolor
dxc
tendinopathi
arthriti
lfx
evalu
one
month
medic
analys
except
ps
match
perform
use
ibm
spss
statist
ver
ibm
co
armonk
ny
usa
kruskalw
test
mannwhitney
test
use
continu
variabl
age
hospit
period
durat
fever
fisher
exact
test
use
categor
variabl
sex
chest
xray
find
antibiot
extrapulmonari
symptom
oxygen
use
icu
hospit
pcd
insert
rehospit
variabl
statist
signific
compar
among
two
group
analyz
mannwhitney
test
test
fisher
exact
test
compar
two
group
compar
ttd
initi
macrolid
treatment
pmc
group
secondari
treatment
group
ps
match
reduc
select
bia
control
potenti
confound
factor
estim
ps
assign
group
calcul
patient
use
multipl
logist
regress
model
follow
covari
age
sex
radiograph
find
mix
infect
pathogen
patient
match
ratio
pmc
cst
pmc
dxc
pmc
lfx
base
greedi
digit
match
algorithm
algorithm
attempt
match
pmc
subject
secondari
treatment
subject
first
digit
ps
pmc
subject
match
match
secondari
treatment
subject
digit
ps
process
algorithm
sequenti
match
ps
patient
correspond
match
exclud
ps
match
perform
use
sa
sa
institut
inc
cari
nc
usa
p
valu
consid
statist
signific
studi
approv
institut
review
board
irb
gachon
univers
gil
medic
center
irb
total
number
subject
met
inclus
criteria
mp
diagnosi
within
studi
period
exclus
studi
criteria
case
macrolideunrespons
mp
pneumonia
enrol
among
case
continu
treat
macrolid
approxim
day
case
treat
addon
cst
continu
macrolid
fourteen
case
treat
secondari
antimicrobi
therapi
dxc
lfx
respect
two
patient
exclud
one
patient
improv
administ
combin
therapi
corticosteroid
lfx
treatment
failur
addon
corticosteroid
alon
patient
treat
corticosteroid
lfx
simultan
median
age
patient
pmc
cst
dxc
lfx
group
year
old
rang
year
old
rang
year
old
rang
year
old
rang
respect
p
patient
dxc
group
significantli
older
pmc
cst
group
p
number
boy
group
respect
p
median
durat
hospit
day
rang
day
rang
day
rang
day
rang
respect
p
tabl
tabl
chang
secondari
treatment
ttd
shortest
cst
group
hour
follow
lfx
hour
dxc
hour
group
fig
number
patient
achiev
defervesc
within
hour
cst
dxc
lfx
group
respect
ttd
initi
macrolid
treatment
compar
match
analysi
pmc
group
secondari
treatment
group
ttd
initi
macrolid
treatment
significantli
differ
pmc
cst
group
tabl
differ
length
hospit
stay
pmc
group
secondari
treatment
group
number
patient
receiv
combin
treatment
thirdgener
cephalosporin
higher
pmc
group
patient
receiv
combin
treatment
vancomycin
need
pcd
insert
identifi
pmc
group
patient
requir
icu
care
differ
rehospit
rate
found
among
group
tabl
patient
whose
clinic
symptom
aggrav
secondari
treatment
side
effect
associ
cst
dxc
lfx
observ
combin
use
gener
cephalosporin
significantli
differ
pmc
corticosteroid
dxc
group
p
incid
macrolid
resist
mp
recent
increas
relat
lifethreaten
refractori
mp
pneumonia
children
sever
studi
macrolid
altern
treatment
mrmp
report
howev
data
therapeut
efficaci
safeti
children
still
limit
compar
therapeut
efficaci
pmc
cst
dxc
lfx
macrolideunrespons
mp
pneumonia
collect
data
safeti
children
patient
achiev
defervesc
within
hour
secondari
treatment
side
effect
observ
cst
dxc
lfx
group
howev
ttd
initi
macrolid
treatment
differ
significantli
pmc
cst
dxc
lfx
group
macrolid
resist
mp
genet
determin
rrna
gene
mutat
differ
clinic
manifest
macrolidesuscept
pneumonia
msmp
mrmp
difficult
clinic
distinguish
mrmp
msmp
howev
report
durat
fever
administr
macrolid
longer
mrmp
msmp
childhood
pneumonia
persist
fever
might
suggest
possibl
infect
mrmp
patient
msmp
achiev
defervesc
within
hour
case
treatment
macrolid
mycoplasma
take
long
time
isol
antibiot
suscept
test
difficult
appli
practic
clinic
situat
molecular
test
confirm
macrolid
resist
current
avail
korean
hospit
except
case
research
purpos
japanes
societi
recommend
chang
antibiot
secondlin
agent
fever
subsid
hour
macrolid
administr
studi
macrolideunrespons
mp
pneumonia
defin
persist
fever
hour
macrolid
treatment
studi
preval
macrolideunrespons
mp
pneumonia
much
lower
preval
mrmp
report
korea
discrep
macrolideresist
macrolideunrespons
indic
patient
mrmp
pneumonia
achiev
defervesc
within
hour
macrolid
administr
matsubara
et
al
demonstr
mrmp
case
show
clinic
improv
within
day
macrolid
treatment
addit
suzuki
et
al
report
fever
resolv
initi
prescrib
macrolid
without
chang
antibiot
treatment
mrmp
infect
appar
treatment
failur
case
seriou
ill
suggest
macrolid
antiinflammatori
effect
well
antimicrobi
effect
inhibit
product
cytokin
human
bronchial
epitheli
cell
data
case
treatment
failur
pmc
group
except
two
case
rehospit
two
case
defervesc
occur
within
hour
without
chang
antibiot
rehospit
previou
report
system
cst
induc
clinic
radiolog
improv
sever
refractori
mp
pneumonia
immun
regulatori
antiinflammatori
effect
cst
could
result
clinic
improv
sever
refractori
mp
pneumonia
studi
cst
improv
fever
shortest
time
hour
compar
medic
similar
report
studi
lee
et
al
report
patient
sever
mp
pneumonia
achiev
defervesc
within
hour
anoth
studi
ttd
approxim
hour
prednisolonetr
patient
recent
sever
studi
suggest
tetracyclin
fluoroquinolon
therapeut
effect
mrmp
children
patient
administ
dxc
minocyclin
achiev
defervesc
within
hour
significantli
shorter
ttd
macrolid
mrmp
group
vs
hour
miyashita
et
al
report
patient
mrmp
quinolon
group
achiev
defervesc
within
hour
initi
antibiot
quinolon
effect
macrolid
mrmp
treatment
p
studi
ttd
dxc
lfx
treatment
hour
hour
respect
addit
patient
achiev
defervesc
within
hour
dxc
lfx
group
respect
tabl
direct
comparison
ttd
pmc
group
secondari
treatment
group
possibl
patient
initi
treat
macrolid
ad
switch
cst
dxc
lfx
therefor
perform
ps
match
adjust
differ
baselin
characterist
among
group
compar
ttd
initi
macrolid
treatment
group
howev
ttd
initi
macrolid
treatment
cst
dxc
lfx
group
differ
match
pmc
group
p
p
p
respect
differ
length
hospit
stay
pmc
group
secondari
treatment
group
tabl
investig
frequenc
use
broadspectrum
antibiot
treatment
communityacquir
pneumonia
children
number
patient
treat
gener
cephalosporin
higher
pmc
group
group
addit
use
vancomycin
observ
pmc
group
tabl
result
suggest
choic
appropri
secondlin
agent
treatment
macrolideunrespons
mp
pneumonia
reduc
use
unnecessari
broadspectrum
antibiot
dxc
lfx
group
side
effect
tooth
discolor
tendinopathi
arthriti
observ
report
tooth
stain
color
chang
observ
children
age
year
old
treat
dxc
howev
dxc
approv
us
food
drug
administr
children
age
year
old
still
contraind
children
younger
year
age
korea
age
indic
tetracyclinebound
drug
includ
dxc
reconsid
addit
risk
cartilag
injuri
lfx
clinic
undetect
children
year
old
easili
revers
subject
treat
lfx
one
case
possibl
relat
drug
therapi
assess
year
differ
compar
group
howev
concern
safeti
tetracyclin
fluoroquinolon
children
still
exist
cautious
use
consider
risk
benefit
children
macrolideunrespons
mp
pneumonia
studi
limit
firstli
studi
perform
retrospect
clinic
inform
might
uncertain
especi
regard
use
durat
macrolid
prescrib
clinic
secondli
number
patient
dxc
lfx
group
small
futur
necessari
carri
prospect
random
studi
conduct
studi
involv
subject
multicent
studi
lastli
igm
antibodi
test
use
diagnos
mp
infect
although
patient
histori
mp
infect
within
past
year
exclud
subject
fals
posit
could
includ
due
prolong
exist
igm
sever
month
past
infect
addit
fals
neg
could
also
exist
due
lack
igm
antibodi
earli
stage
howev
altern
method
isol
molecular
detect
mp
differenti
asymptomat
carriag
mp
nasopharynx
infect
mp
pneumonia
studi
macrolid
resist
mp
determin
molecular
analysi
suscept
test
identifi
studi
base
actual
treatment
cours
mp
pneumonia
clinic
set
fever
persist
despit
use
macrolid
necessari
consid
secondari
treatment
without
result
antimicrobi
suscept
compar
therapeut
efficaci
secondari
treatment
clinic
assess
macrolideunrespons
mp
pneumonia
macrolideunrespons
mp
pneumonia
patient
achiev
defervesc
within
hour
cst
addon
treatment
chang
dxc
lfx
side
effect
observ
secondari
treatment
group
howev
secondari
treatment
shorten
durat
fever
hospit
compar
pmc
treatment
largescal
prospect
studi
need
guid
appropri
treatment
children
mycoplasma
pneumonia
